Joshua Fitch is the senior editor for Contemporary Pediatrics. He joined the brand in March of 2023 as an editor before being promoted to senior editor in January 2024. Fitch graduated from Youngstown ...

Welcome to this Contemporary Pediatrics poll. Take a look at the following case below. After reading through the description, choose a multiple-choice answer and try to guess the correct patient ...

On June 9, 2025, the FDA approved Merck's monoclonal antibody clesrovimab (Enflonsia) to protect infants from respiratory syncytial virus (RSV) disease during their first RSV season, according to a ...

We know hydration matters—but in the heat of summer, it matters even more. Between sports camps, pool days, and longer stretches of outdoor play, it’s easy for kids to fall behind on fluid intake ...

The case: A healthy 12-month-old girl presented with one small skin lesion over the right heel (Figure 1) for one month. On examination, her right lateral heel showed a round white pearl like hard ...

The FDA has approved an expanded pediatric indication for the SONU Band (SoundHealth) for at-home treatment of moderate-to-severe nasal congestion because of allergic and non-allergic rhinitis in ...

Invasive Staphylococcus aureus infections remain a major cause of illness and death in neonatal intensive care units (NICUs), particularly among very low birth weight (VLBW) infants, according to a ...

The FDA will not meet a prescription drug user fee act (PDUFA) date of June 17, 2025, for a decision regarding the potential approval of sebetralstat (KalVista Pharmaceuticals) to treat hereditary ...

May 2025 brought a series of critical developments that continue to shape pediatric care and child health nationwide. From shifts in vaccine policy to new evidence on mental health and chronic disease ...

The June 9, 2025, FDA approval of clesrovimab (Enflonsia; Merck) marked another advancement for the prevention of respiratory syncytial virus (RSV) disease in infants, especially during their first ...

Among children aged 1 to 11 years, new data for Valneva's chikungunya vaccine, IXCHIQ, revealed antibody persistence and safety for up to 6 months for the single-shot vaccine in both half- and ...

Despite decades of scientific progress, invasive Staphylococcus aureus infections remain a persistent and deadly threat to infants in neonatal intensive care units (NICUs)—especially those born ...